Chapter 4 introduced the autonomic nervous system as a two-division, two-neuron architecture that governs involuntary function throughout the body. Module 1 of Chapter 5 takes you deeper into the molecular machinery that makes adrenergic pharmacology possible — the receptors themselves. Every drug you will encounter in Chapters 5 and 6 exerts its effects by interacting with one or more adrenergic receptor subtypes. Understanding which receptor is activated or blocked, where that receptor is located, and what signal transduction cascade it triggers is the foundational skill that lets you predict drug effects rather than memorize them. Work through these questions carefully — the receptor subtype framework you build here will carry you through vasopressors, antihypertensives, bronchodilators, and dozens of other drug classes you have not yet studied.
1. Adrenergic receptors are divided into two major families — alpha and beta — each with clinically important subtypes. Which of the following correctly matches the receptor subtype with its primary coupling protein (G protein) and the downstream signal transduction consequence of its activation?
A) Alpha-1 adrenergic receptors couple to Gs, activating adenylyl cyclase (an enzyme that converts ATP to cAMP) and increasing intracellular cyclic AMP (cAMP), which activates protein kinase A (PKA) and produces smooth muscle contraction
B) Alpha-1 adrenergic receptors couple to Gq, activating phospholipase C (PLC), which cleaves PIP2 into inositol trisphosphate (IP3) and diacylglycerol (DAG), leading to intracellular calcium release and smooth muscle contraction
C) Alpha-1 adrenergic receptors couple to Gi, inhibiting adenylyl cyclase and reducing intracellular cAMP, which reduces protein kinase A activity and produces smooth muscle relaxation
D) Alpha-1 adrenergic receptors couple to Gs, activating adenylyl cyclase and increasing cAMP, which activates protein kinase A and produces vasodilation through smooth muscle relaxation
E) Alpha-1 adrenergic receptors couple to Go, activating phosphodiesterase (PDE) and reducing intracellular cAMP through accelerated degradation, producing smooth muscle contraction through a cGMP-independent pathway
ANSWER: B
Rationale:
Alpha-1 adrenergic receptors are Gq-coupled receptors. When norepinephrine (NE) or epinephrine binds alpha-1 receptors, the activated Gq protein stimulates phospholipase C (PLC), which cleaves the membrane phospholipid PIP2 (phosphatidylinositol 4,5-bisphosphate) into two second messengers: IP3 (inositol trisphosphate), which triggers calcium release from the endoplasmic reticulum, and DAG (diacylglycerol), which activates protein kinase C (PKC). The resulting rise in intracellular calcium activates myosin light chain kinase (MLCK), producing smooth muscle contraction — this is the mechanism underlying vasoconstriction, pupillary dilation, and urethral sphincter contraction produced by alpha-1 agonists. This Gq/PLC/IP3 pathway is distinct from the Gs/cAMP pathway used by beta receptors and must be clearly distinguished.
Option A: Option A incorrectly assigns Gs coupling to alpha-1 receptors. Gs coupling with adenylyl cyclase activation and cAMP elevation is the mechanism of beta-1 and beta-2 adrenergic receptors, not alpha-1 receptors.
Option C: Option C incorrectly assigns Gi coupling and cAMP reduction to alpha-1 receptors. Gi coupling with inhibition of adenylyl cyclase is the mechanism of alpha-2 adrenergic receptors, not alpha-1 receptors.
Option D: Option D is incorrect on two counts: alpha-1 receptors couple to Gq (not Gs), and alpha-1 activation produces vasoconstriction (not vasodilation); Gs-coupled receptors activate adenylyl cyclase and elevate cAMP, which promotes smooth muscle relaxation — the opposite of the alpha-1 vasoconstrictor effect.
Option E: Option E describes a non-existent Go/phosphodiesterase mechanism. While Go proteins exist, alpha-1 receptor signaling proceeds through Gq/PLC, not Go/PDE.
2. Beta-2 adrenergic receptors are expressed in bronchial smooth muscle, uterine smooth muscle, and vascular smooth muscle supplying skeletal muscle. Which of the following correctly describes the signal transduction pathway activated by beta-2 receptor stimulation and the physiological consequence in bronchial smooth muscle?
A) Beta-2 receptors couple to Gq, activating phospholipase C and increasing intracellular IP3 and DAG; the resulting calcium release activates myosin light chain kinase (MLCK), producing bronchoconstriction
B) Beta-2 receptors couple to Gi, inhibiting adenylyl cyclase and reducing cAMP; the reduction in protein kinase A activity decreases phosphorylation of myosin light chain kinase (MLCK), producing bronchodilation
C) Beta-2 receptors couple to Gs, activating adenylyl cyclase and increasing cAMP; elevated cAMP activates protein kinase A (PKA), which phosphorylates and inactivates myosin light chain kinase (MLCK), producing bronchial smooth muscle relaxation
D) Beta-2 receptors couple to Gs, activating adenylyl cyclase and increasing cAMP; elevated cAMP directly opens calcium channels in the sarcoplasmic reticulum, flooding the cytoplasm with calcium and producing bronchial smooth muscle contraction
E) Beta-2 receptors couple to G12/13, activating Rho kinase and producing cytoskeletal rearrangement that tightens bronchial smooth muscle tone independent of calcium or cAMP
ANSWER: C
Rationale:
Beta-2 adrenergic receptors couple to Gs (stimulatory G protein), which activates adenylyl cyclase, converting ATP to cyclic AMP (cAMP). Elevated intracellular cAMP activates protein kinase A (PKA). In bronchial smooth muscle, PKA phosphorylates myosin light chain kinase (MLCK), inactivating it — this prevents myosin phosphorylation, reduces cross-bridge cycling, and produces smooth muscle relaxation (bronchodilation). This is the molecular basis for beta-2 agonists such as albuterol and salbutamol as bronchodilators in asthma and COPD. The Gs/cAMP/PKA/MLCK-inactivation cascade is the defining signal transduction sequence for all beta receptor subtypes, though the tissue expressing the receptor determines the physiological outcome (bronchodilation in airway smooth muscle, vasodilation in skeletal muscle vasculature, uterine relaxation).
Option A: Option A incorrectly assigns Gq coupling and bronchoconstriction to beta-2 receptors. Gq/PLC/IP3/calcium signaling producing smooth muscle contraction is the alpha-1 receptor pathway, not beta-2.
Option B: Option B incorrectly assigns Gi coupling and cAMP reduction to beta-2 receptors. Gi-mediated adenylyl cyclase inhibition is the alpha-2 receptor mechanism. Furthermore, reduced PKA activity would impair MLCK inactivation, maintaining rather than reducing bronchial tone.
Option D: Option D is incorrect: although beta-2 receptors do couple to Gs and elevate cAMP, cAMP does not directly open sarcoplasmic reticulum calcium channels; cAMP acts through PKA-mediated phosphorylation of downstream targets, and in bronchial smooth muscle the net effect of elevated cAMP is relaxation (bronchodilation), not contraction — the opposite of what Option D states.
Option E: Option E describes a G12/13/Rho kinase pathway that is not the mechanism of beta-2 receptor signaling. This pathway is relevant to certain contractile mechanisms but is not activated by beta-2 adrenergic receptors.
3. Alpha-2 adrenergic receptors are expressed at multiple anatomical locations that have distinct pharmacological importance. Which of the following correctly identifies the two most clinically significant locations of alpha-2 receptors and the consequence of their activation at each site?
A) Presynaptic sympathetic nerve terminals (autoreceptors) — where alpha-2 activation inhibits further norepinephrine release, providing negative feedback to limit sympathetic outflow; and in the brainstem (nucleus tractus solitarius and rostral ventrolateral medulla) — where alpha-2 activation reduces central sympathetic drive, decreasing heart rate, blood pressure, and peripheral vascular resistance
B) Presynaptic sympathetic nerve terminals (autoreceptors) — where alpha-2 activation stimulates further norepinephrine release, amplifying the sympathetic signal; and in the brainstem — where alpha-2 activation increases central sympathetic drive, elevating blood pressure
C) Postsynaptic vascular smooth muscle — where alpha-2 activation produces vasodilation through Gi-mediated inhibition of adenylyl cyclase and cAMP reduction; and in the heart — where alpha-2 activation increases contractility by enhancing calcium influx through L-type channels
D) Postsynaptic vascular smooth muscle — where alpha-2 activation produces vasoconstriction equivalent to alpha-1 receptor activation; and in pancreatic beta cells — where alpha-2 activation stimulates insulin secretion to counteract catecholamine-induced hyperglycemia
E) Presynaptic parasympathetic nerve terminals (heteroreceptors) — where alpha-2 activation inhibits acetylcholine release, reducing parasympathetic tone at the heart and producing tachycardia; and in the kidney — where alpha-2 activation stimulates renin release and activates the RAAS
ANSWER: A
Rationale:
Alpha-2 adrenergic receptors are Gi-coupled receptors whose activation inhibits adenylyl cyclase, reducing cAMP. Their two most pharmacologically important locations are: (1) Presynaptic sympathetic nerve terminals, where they function as autoreceptors — when released norepinephrine accumulates in the synapse and binds presynaptic alpha-2 receptors, it inhibits further NE release, constituting a negative feedback loop that prevents excessive sympathetic activation. This mechanism explains why alpha-2 agonists like clonidine can reduce peripheral NE release. (2) The central nervous system, particularly the brainstem nuclei (nucleus tractus solitarius, rostral ventrolateral medulla) — activation of these central alpha-2 receptors reduces sympathetic outflow to the heart and vasculature, lowering heart rate, blood pressure, and peripheral vascular resistance. Clonidine and methyldopa exploit this central mechanism as antihypertensives.
Option B: Option B reverses the effect of presynaptic alpha-2 activation. Presynaptic alpha-2 autoreceptor activation inhibits (not stimulates) NE release. This negative feedback is fundamental to understanding adrenergic pharmacology.
Option C: Option C incorrectly describes postsynaptic vascular alpha-2 effects as vasodilation. While alpha-2 receptors do exist postsynaptically on some vascular smooth muscle cells and their activation can produce vasoconstriction, the dominant pharmacological actions are the presynaptic and central effects described in
Option D: Option D incorrectly states that alpha-2 activation stimulates insulin secretion. Alpha-2 receptor activation in pancreatic beta cells inhibits (not stimulates) insulin secretion — this is one reason catecholamine excess causes hyperglycemia.
Option E: Option E incorrectly identifies the presynaptic location as parasympathetic terminals and incorrectly states that alpha-2 activation stimulates renin release. Alpha-2 activation in the kidney inhibits renin release.
4. A pharmacology student is asked to identify the adrenergic receptor subtype responsible for mediating heart rate increase in response to sympathetic stimulation. Which of the following correctly identifies the receptor subtype, its location, and its signal transduction mechanism leading to increased heart rate?
A) Alpha-1 receptors in the sinoatrial (SA) node — Gq-coupled; activation increases IP3 and DAG, raising intracellular calcium, which accelerates spontaneous depolarization of SA nodal pacemaker cells and increases heart rate
B) Beta-2 receptors in the SA node — Gs-coupled; activation increases cAMP and PKA activity, which phosphorylates the funny current (If) channel and L-type calcium channels, accelerating pacemaker depolarization and increasing heart rate
C) Beta-1 receptors in the SA node — Gs-coupled; activation increases cAMP and PKA activity, which phosphorylates the funny current (If) channel and L-type calcium channels, accelerating pacemaker depolarization and increasing the rate of spontaneous firing
D) Alpha-2 receptors in the SA node — Gi-coupled; activation inhibits adenylyl cyclase, reducing cAMP; paradoxically, reduced PKA activity disinhibits pacemaker channels, accelerating depolarization and increasing heart rate
E) Beta-3 receptors in the SA node — Gs-coupled; activation increases cAMP and reduces the refractory period of SA nodal cells through PKA-mediated phosphorylation of potassium channels, producing chronotropy
ANSWER: C
Rationale:
Beta-1 adrenergic receptors are the dominant mediators of sympathetic chronotropy (heart rate increase) in the sinoatrial (SA) node. Beta-1 receptors are Gs-coupled — activation stimulates adenylyl cyclase, raising intracellular cAMP, which activates PKA. PKA phosphorylates two key ion channels in SA nodal pacemaker cells: (1) the HCN channel (hyperpolarization-activated cyclic nucleotide-gated channel, also called the funny current or If channel), which accelerates the rate of spontaneous diastolic depolarization; and (2) L-type calcium channels, which increase calcium influx during the upstroke, steepening depolarization. The net result is a faster pacemaker rate — positive chronotropy. Beta-1 receptors are also the dominant mediators of positive inotropy (increased contractility) in the ventricles. The cardiac selectivity of beta-1 receptors is why cardioselective beta blockers (metoprolol, atenolol) target beta-1 to reduce heart rate and contractility without blocking beta-2-mediated bronchodilation.
Option A: Option A incorrectly assigns alpha-1 receptors as the mediators of chronotropy. Alpha-1 receptors have minimal direct effect on SA node firing rate; their primary cardiac action is modest positive inotropy in ventricular myocardium.
Option B: Option B correctly identifies the Gs-cAMP-PKA-If/L-type calcium channel mechanism for chronotropy but incorrectly names the receptor subtype as beta-2; the SA node expresses predominantly beta-1 receptors, and beta-1 activation is the primary mediator of catecholamine-induced tachycardia; beta-2 receptors are expressed at much lower density in SA nodal tissue and are not the dominant subtype responsible for heart rate acceleration.
Option D: Option D incorrectly assigns alpha-2 receptors and Gi coupling to SA node chronotropy, and the proposed mechanism (paradoxical disinhibition) has no pharmacological basis.
Option E: Option E incorrectly assigns beta-3 receptors to SA node chronotropy. Beta-3 receptors are expressed in adipose tissue and the bladder detrusor; their cardiac expression is minimal and their role in chronotropy is not clinically established.
5. Beta-3 adrenergic receptors are the least clinically prominent of the beta receptor subtypes but have specific therapeutic relevance. Which of the following correctly identifies the primary tissue expression of beta-3 receptors and their pharmacological significance?
A) Beta-3 receptors are expressed primarily in cardiac ventricular myocardium, where their Gs-coupled activation increases contractility; they are targeted by dobutamine in the treatment of acute decompensated heart failure
B) Beta-3 receptors are expressed primarily in bronchial smooth muscle, where their Gs-coupled activation produces bronchodilation; they provide a backup bronchodilatory pathway when beta-2 receptors are downregulated in chronic asthma
C) Beta-3 receptors are expressed primarily in vascular smooth muscle, where their Gi-coupled activation produces vasodilation; they are targeted by beta-3 agonists to reduce systemic vascular resistance in pulmonary arterial hypertension
D) Beta-3 receptors are expressed primarily in adipose tissue (mediating lipolysis) and in the detrusor muscle of the urinary bladder (mediating relaxation); mirabegron, a selective beta-3 agonist, exploits detrusor relaxation to treat overactive bladder (OAB)
E) Beta-3 receptors are expressed primarily in the liver, where their Gs-coupled activation stimulates glycogenolysis and gluconeogenesis; they are clinically relevant in the metabolic response to catecholamine excess in pheochromocytoma
ANSWER: D
Rationale:
Beta-3 adrenergic receptors are expressed most prominently in two tissues with distinct physiological roles: (1) Adipose tissue — where beta-3 activation stimulates lipolysis (breakdown of stored triglycerides into free fatty acids and glycerol), contributing to thermogenesis and energy mobilization during sympathetic activation; (2) Detrusor smooth muscle of the urinary bladder — where beta-3 activation produces relaxation of the detrusor, increasing bladder storage capacity. This second action is the basis for mirabegron (a selective beta-3 agonist) approved for overactive bladder (OAB) — by relaxing the detrusor, mirabegron reduces urgency and frequency without the anticholinergic side effects of muscarinic antagonists. Beta-3 receptors are Gs-coupled like beta-1 and beta-2, but their tissue distribution and downstream effects differ markedly from the cardiac (beta-1) and pulmonary (beta-2) receptor subtypes.
Option A: Option A incorrectly assigns beta-3 receptors to cardiac ventricular myocardium and states that dobutamine targets them. Dobutamine is a selective beta-1 agonist (with some beta-2 activity); cardiac contractility is mediated by beta-1, not beta-3, receptors.
Option B: Option B incorrectly assigns beta-3 receptors to bronchial smooth muscle. Bronchodilation is mediated primarily by beta-2 receptors; beta-3 receptors play no established role in airway pharmacology.
Option C: Option C incorrectly assigns beta-3 receptors to vascular smooth muscle and incorrectly states Gi coupling. Beta-3 receptors are Gs-coupled and are not the primary mediators of vascular tone regulation.
Option E: Option E incorrectly states that beta-3 receptors are expressed primarily in the liver. The liver does respond to catecholamines metabolically, but primarily through beta-2 and alpha-1 receptors, not beta-3. The primary beta-3 expressing tissues are adipose and bladder detrusor, not hepatic parenchyma.
6. A physiologist is comparing the downstream consequences of activating Gs-coupled receptors versus Gi-coupled receptors in the context of adrenergic pharmacology. Which of the following correctly describes how Gs and Gi coupling produce opposing physiological effects through the same second messenger system?
A) Gs coupling activates phospholipase C, increasing IP3 and DAG; Gi coupling inhibits phospholipase C, reducing IP3 and DAG; their opposing effects on calcium mobilization produce opposite smooth muscle outcomes — contraction versus relaxation
B) Gs coupling activates adenylyl cyclase, increasing cAMP and PKA activity; Gi coupling inhibits adenylyl cyclase, reducing cAMP and PKA activity; in the SA node, Gs-mediated cAMP elevation accelerates pacemaker firing while Gi-mediated cAMP reduction slows it — which is why beta-1 agonists increase heart rate and why muscarinic M2 receptor activation (also Gi-coupled) slows it
C) Gs coupling opens voltage-gated calcium channels directly through the alpha subunit of the G protein; Gi coupling closes these same channels; the net calcium flux determines whether smooth muscle contracts or relaxes
D) Gs and Gi produce identical downstream effects on cAMP but differ in their effects on potassium channels — Gs-coupled receptors close GIRK channels (G protein-gated inwardly rectifying potassium channels) while Gi-coupled receptors open them, producing hyperpolarization
E) Gs coupling activates protein kinase C through DAG; Gi coupling activates protein kinase A through cAMP; the two kinases phosphorylate overlapping but distinct substrate proteins, producing complementary rather than opposing physiological effects
ANSWER: B
Rationale:
Gs (stimulatory G protein) and Gi (inhibitory G protein) exert opposing effects on adenylyl cyclase — the enzyme that converts ATP to cyclic AMP (cAMP). Gs activates adenylyl cyclase, raising cAMP and activating PKA. Gi inhibits adenylyl cyclase, lowering cAMP and reducing PKA activity. In the SA node, this opposing regulation is clinically critical: beta-1 adrenergic receptors (Gs-coupled) increase cAMP, accelerating pacemaker firing through PKA-mediated phosphorylation of HCN channels and L-type calcium channels — producing tachycardia. Muscarinic M2 receptors (also Gi-coupled) reduce cAMP, slowing pacemaker firing — producing bradycardia. This is why atropine (a muscarinic antagonist that blocks M2-mediated Gi signaling) increases heart rate by removing the parasympathetic brake, and why beta blockers (blocking beta-1/Gs signaling) slow heart rate. Understanding Gs vs Gi as a push-pull system on adenylyl cyclase/cAMP is foundational to autonomic pharmacology.
Option A: Option A incorrectly assigns Gs to phospholipase C activation. Gs couples to adenylyl cyclase, not phospholipase C. PLC activation is the mechanism of Gq-coupled receptors (alpha-1 adrenergic, muscarinic M1/M3).
Option C: Option C incorrectly states that Gs directly opens voltage-gated calcium channels through the G protein alpha subunit. While L-type calcium channels are phosphorylated by PKA downstream of cAMP elevation, Gs does not directly gate calcium channels — it acts through the adenylyl cyclase/cAMP/PKA cascade.
Option D: Option D incorrectly states that Gs and Gi produce identical effects on cAMP. Their primary distinction is their opposing regulation of adenylyl cyclase. While Gi does activate GIRK channels through the Gbetagamma subunit, this is a secondary effect, not the primary mechanism distinguishing Gs from Gi.
Option E: Option E incorrectly assigns DAG/PKC to Gs and cAMP/PKA to Gi, reversing their actual mechanisms. Gs signals through cAMP/PKA; DAG/PKC is the downstream pathway of Gq-coupled receptors.
7. The concept of receptor selectivity is central to adrenergic pharmacology. Endogenous catecholamines differ in their relative affinity for alpha and beta receptor subtypes, and this difference determines their physiological effects. Which of the following correctly ranks norepinephrine (NE), epinephrine, and isoproterenol in terms of their relative alpha versus beta receptor selectivity, and correctly predicts the dominant cardiovascular consequence of each?
A) Norepinephrine has high affinity for alpha-1 and beta-1 receptors but negligible beta-2 affinity — producing vasoconstriction (alpha-1) and increased cardiac contractility/rate (beta-1) with minimal vasodilation; epinephrine has high affinity for alpha-1, beta-1, and beta-2 receptors — producing mixed vasoconstriction and vasodilation depending on vascular bed, increased cardiac contractility and rate, and bronchodilation; isoproterenol is a non-selective pure beta agonist with negligible alpha affinity — producing vasodilation (beta-2), bronchodilation (beta-2), and marked tachycardia with increased contractility (beta-1), with no vasoconstriction
B) Norepinephrine is a pure alpha agonist with no beta receptor affinity — producing vasoconstriction only, with no cardiac effects; epinephrine has equal affinity for all receptor subtypes — producing balanced cardiovascular and pulmonary effects; isoproterenol is a pure alpha-1 agonist — producing intense vasoconstriction with no cardiac or pulmonary effects
C) All three catecholamines have identical receptor affinity profiles and produce identical cardiovascular effects at equivalent doses — clinical differences between them are due entirely to differences in their rate of metabolism by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO)
D) Norepinephrine and epinephrine have identical receptor profiles; isoproterenol differs only by having higher potency at all receptor subtypes, producing more intense versions of the same cardiovascular effects as NE and epinephrine at lower doses
E) Isoproterenol has higher alpha-1 affinity than either norepinephrine or epinephrine — producing more intense vasoconstriction; norepinephrine has the highest beta-2 affinity of the three — producing the most bronchodilation; epinephrine has negligible alpha or beta receptor activity at therapeutic doses
ANSWER: A
Rationale:
The receptor selectivity hierarchy of the three classic catecholamines is a foundational concept in adrenergic pharmacology. Norepinephrine has high affinity for alpha-1, alpha-2, and beta-1 receptors but very low affinity for beta-2 receptors — it produces pronounced vasoconstriction (alpha-1) and positive cardiac inotropy/chronotropy (beta-1), but minimal beta-2-mediated vasodilation or bronchodilation. Epinephrine has high affinity for alpha-1, alpha-2, beta-1, and beta-2 receptors — at low doses, beta-2-mediated vasodilation in skeletal muscle vasculature may predominate, but at higher doses alpha-1 vasoconstriction dominates; epinephrine also produces marked bronchodilation (beta-2) and strong cardiac stimulation (beta-1). Isoproterenol is a synthetic non-selective beta agonist with negligible alpha receptor affinity — it produces pure beta effects: vasodilation (beta-2), bronchodilation (beta-2), and intense positive chronotropy and inotropy (beta-1), with no alpha-mediated vasoconstriction.
Option B: Option B incorrectly states that norepinephrine is a pure alpha agonist. NE has significant beta-1 activity, producing positive chronotropy and inotropy. It is not devoid of beta receptor effects.
Option C: Option C incorrectly states that all three catecholamines have identical receptor profiles. Their receptor selectivity differences are fundamental and pharmacologically distinct — metabolism differences do not account for their differing clinical profiles.
Option D: Option D incorrectly equates NE and epinephrine receptor profiles. While they share some receptor overlap, NE has minimal beta-2 activity whereas epinephrine has significant beta-2 activity — a clinically important distinction.
Option E: Option E reverses the established rank-order potency profile of all three catecholamines: isoproterenol has negligible alpha-1 affinity (not high alpha-1 affinity) and is essentially a pure beta agonist; norepinephrine has low beta-2 affinity (not the highest of the three) because it lacks the N-methyl group that confers beta-2 selectivity; and epinephrine has potent activity at both alpha and beta receptors at therapeutic doses, not negligible activity as stated.
8. Presynaptic alpha-2 autoreceptors serve as a negative feedback mechanism regulating norepinephrine (NE) release from sympathetic nerve terminals. A pharmacologist tests two drugs: Drug X activates presynaptic alpha-2 receptors, and Drug Y blocks presynaptic alpha-2 receptors. Which of the following correctly predicts the effect of each drug on NE release and the resulting cardiovascular consequence?
A) Drug X (alpha-2 agonist) increases NE release from sympathetic terminals by activating the autoreceptor positive feedback loop, producing hypertension and tachycardia; Drug Y (alpha-2 antagonist) decreases NE release by blocking the autoreceptor, reducing sympathetic tone and producing hypotension
B) Drug X (alpha-2 agonist) has no effect on NE release because presynaptic autoreceptors only modulate acetylcholine, not norepinephrine; Drug Y (alpha-2 antagonist) blocks non-adrenergic receptors on the vascular endothelium, producing vasodilation independent of NE
C) Drug X (alpha-2 agonist) and Drug Y (alpha-2 antagonist) both increase NE release through different mechanisms — Drug X by receptor desensitization and Drug Y by receptor blockade — both producing sympathetic activation
D) Drug X (alpha-2 agonist) inhibits NE release from sympathetic terminals by activating the inhibitory autoreceptor, reducing synaptic NE and producing a reduction in sympathetic tone; Drug Y (alpha-2 antagonist) blocks the inhibitory autoreceptor, removing the negative feedback brake on NE release and increasing synaptic NE — producing enhanced sympathetic effects including increased blood pressure and heart rate
E) Drug X (alpha-2 agonist) reduces NE release but simultaneously activates postsynaptic alpha-2 receptors on vascular smooth muscle to produce vasoconstriction, making the net cardiovascular effect unpredictable; Drug Y (alpha-2 antagonist) increases NE release but simultaneously blocks postsynaptic vascular alpha-2 receptors, producing vasodilation that exactly cancels the sympathetic effect
ANSWER: D
Rationale:
Presynaptic alpha-2 autoreceptors function as a negative feedback mechanism — when NE accumulates in the synapse and binds the presynaptic alpha-2 receptor, Gi-mediated inhibition of adenylyl cyclase reduces cAMP in the nerve terminal, inhibiting calcium-dependent vesicle fusion and reducing further NE exocytosis. Drug X (an alpha-2 agonist) mimics this feedback, inhibiting NE release and thereby reducing sympathetic tone — this is the mechanism of centrally and peripherally acting alpha-2 agonists like clonidine. Drug Y (an alpha-2 antagonist, such as yohimbine) blocks the autoreceptor, preventing NE from suppressing its own release — removing the negative feedback brake — resulting in enhanced NE release and increased sympathetic activity. Yohimbine was historically used to study adrenergic mechanisms and is sometimes used in autonomic testing; increased NE release produces tachycardia and hypertension.
Option A: Option A reverses the effects of both drugs. Alpha-2 agonists inhibit (not increase) NE release; alpha-2 antagonists increase (not decrease) NE release by removing the autoreceptor feedback.
Option B: Option B incorrectly states that presynaptic autoreceptors only modulate acetylcholine. Alpha-2 autoreceptors are specifically located on noradrenergic terminals to regulate NE release; they are distinct from heteroreceptors that regulate other neurotransmitters.
Option C: Option C incorrectly states that both drugs increase NE release. Drug X (agonist) activates the inhibitory autoreceptor and reduces NE release; only Drug Y increases NE release by blocking the negative feedback.
Option E: Option E incorrectly assumes that presynaptic and postsynaptic alpha-2 effects exactly cancel each other, making net cardiovascular outcomes unpredictable; in clinical practice the net effects of alpha-2 agonists and antagonists are well-characterized and predictable — alpha-2 agonists (e.g., clonidine) produce net antihypertensive effects because the presynaptic reduction in NE release and CNS sympatholysis predominate over any postsynaptic vasoconstrictor effect; the premise of pharmacological unpredictability stated in Option E is not supported by clinical or experimental evidence.
9. A medical student is reviewing adrenergic receptor pharmacology and asks: "If both alpha-1 and alpha-2 receptors are activated by norepinephrine and both ultimately produce vasoconstriction in some vascular beds, why does it matter which subtype we distinguish clinically?" Which of the following best explains the clinical importance of distinguishing alpha-1 from alpha-2 receptor subtypes?
A) The distinction is primarily academic — alpha-1 and alpha-2 receptors produce identical physiological effects in all tissues, differ only in their anatomical locations within blood vessel walls, and have no drug selectivity differences that matter clinically
B) Alpha-1 receptors mediate vasodilation while alpha-2 receptors mediate vasoconstriction — drugs that selectively target alpha-1 receptors are used as vasopressors while drugs that target alpha-2 receptors are used as vasodilators
C) Alpha-1 and alpha-2 receptors differ in their location (postsynaptic vs presynaptic/central), their signal transduction pathways (Gq vs Gi), their tissue distribution, and their drug selectivity — selective alpha-1 antagonists (prazosin) treat hypertension and BPH without the rebound NE release caused by blocking presynaptic alpha-2 autoreceptors; selective alpha-2 agonists (clonidine) reduce central sympathetic outflow to treat hypertension without the vasoconstriction caused by postsynaptic alpha-1 activation; these distinctions directly determine drug choice and side effect profiles
D) Alpha-1 receptors are found only in the peripheral vasculature and alpha-2 receptors are found only in the CNS — drugs that cross the blood-brain barrier activate alpha-2 receptors exclusively while peripherally restricted drugs activate only alpha-1 receptors
E) The distinction matters only for drug interactions — alpha-1 and alpha-2 receptors compete for the same binding site on norepinephrine, and selective alpha-1 drugs displace NE from alpha-2 receptors, increasing free NE available for beta receptor activation
ANSWER: C
Rationale:
The clinical distinction between alpha-1 and alpha-2 receptor subtypes is pharmacologically fundamental, not merely academic. The key differences are: (1) Location — alpha-1 receptors are predominantly postsynaptic on vascular smooth muscle, iris dilator, and urethral sphincter; alpha-2 receptors are predominantly presynaptic (autoreceptors on noradrenergic terminals) and in the brainstem (where they reduce central sympathetic outflow); (2) Signal transduction — alpha-1 uses Gq/PLC/IP3/calcium; alpha-2 uses Gi/adenylyl cyclase inhibition/cAMP reduction; (3) Drug selectivity with distinct clinical applications — prazosin and related alpha-1 selective antagonists lower blood pressure and reduce urethral tone in BPH without affecting presynaptic alpha-2 autoreceptors (avoiding the reflex NE surge that non-selective alpha blockade would produce); clonidine and methyldopa as alpha-2 selective agonists reduce central sympathetic drive to treat hypertension. These distinctions make the alpha-1/alpha-2 dichotomy one of the most clinically consequential receptor subtype distinctions in pharmacology.
Option A: Option A incorrectly dismisses the clinical importance of the alpha-1/alpha-2 distinction. The differences in location, signal transduction, and drug selectivity are clinically decisive and determine which drugs are used for which conditions.
Option B: Option B reverses the physiological effects — alpha-1 receptors mediate vasoconstriction (not vasodilation) and alpha-2 receptors, while having a presynaptic inhibitory role, can also produce vasoconstriction postsynaptically. Neither subtype primarily mediates vasodilation.
Option D: Option D incorrectly states that alpha-1 receptors are found only peripherally and alpha-2 receptors only centrally. Both subtypes are present in peripheral tissues; alpha-2 receptors have important presynaptic roles peripherally as well as central roles.
Option E: Option E describes a non-existent competitive displacement mechanism between alpha-1 and alpha-2 drugs at NE binding. Receptor subtypes have distinct binding pockets and selectivity is determined by molecular structure, not displacement of NE between receptors.
10. A 28-year-old woman with a history of asthma is prescribed a non-selective beta blocker (propranolol) by a physician unfamiliar with her pulmonary history. Within two hours of her first dose she develops acute bronchospasm requiring emergency bronchodilator therapy. Using adrenergic receptor subtype knowledge, which of the following best explains the pharmacological mechanism of her bronchospasm?
A) Propranolol crosses the blood-brain barrier and activates central alpha-2 receptors, which reduce sympathetic drive to the bronchial smooth muscle, causing it to lose its normal bronchodilatory tone and contract
B) Propranolol blocks alpha-1 receptors in the bronchial vasculature, producing mucosal edema and airway narrowing; the beta receptor subtypes are not involved in this adverse effect
C) Propranolol blocks beta-1 receptors in the SA node, reducing heart rate and cardiac output; the reduced pulmonary blood flow decreases bronchial oxygen delivery, causing ischemic bronchoconstriction
D) Propranolol directly activates muscarinic M3 receptors on bronchial smooth muscle through an off-target pharmacodynamic mechanism, producing acetylcholine-like bronchoconstriction independent of adrenergic receptor blockade
E) Propranolol blocks beta-2 adrenergic receptors in bronchial smooth muscle, preventing endogenous epinephrine and sympathetic tone from maintaining airway dilation through the Gs/cAMP/PKA/MLCK-inactivation pathway; in a patient with asthma whose airways are already hyperreactive, removal of this beta-2-mediated bronchodilatory tone tips the balance toward bronchoconstriction
ANSWER: E
Rationale:
This case illustrates the critical clinical consequence of using a non-selective beta blocker in an asthmatic patient. Bronchial smooth muscle tone is maintained in a relaxed state partly through beta-2 adrenergic receptor activation — endogenous epinephrine (circulating) and local sympathetic tone activate beta-2 receptors, raising cAMP via Gs, activating PKA, and inactivating myosin light chain kinase (MLCK) to maintain bronchodilation. In healthy individuals, blocking beta-2 receptors with propranolol may cause only mild airway changes. However, in patients with asthma — whose airways have underlying hyperreactivity (increased sensitivity to bronchoconstrictor stimuli, reduced baseline bronchodilatory reserve, and often inflammatory airway changes) — blocking beta-2 receptors removes the sympathetic bronchodilatory brake, allowing unopposed parasympathetic (muscarinic M3) bronchoconstriction to predominate, precipitating acute bronchospasm. This is why non-selective beta blockers are contraindicated in asthma; beta-1 selective agents (metoprolol, atenolol) are preferred when beta blockade is necessary in asthmatic patients.
Option A: Option A incorrectly attributes the bronchospasm to central alpha-2 receptor activation. Propranolol is a beta blocker with no alpha-2 agonist activity; its bronchospastic effect is peripheral and mediated by beta-2 blockade, not central alpha-2 activation.
Option B: Option B incorrectly attributes the bronchospasm to alpha-1 receptor blockade. Propranolol has negligible alpha-1 antagonist activity, and mucosal edema from vascular alpha-1 blockade is not the mechanism of propranolol-induced bronchospasm.
Option C: Option C incorrectly attributes the bronchospasm to reduced pulmonary blood flow and ischemia. Propranolol-induced bronchospasm is a direct pharmacodynamic consequence of beta-2 blockade in airway smooth muscle, not a secondary ischemic phenomenon.
Option D: Option D incorrectly attributes the bronchospasm to direct muscarinic M3 receptor activation by propranolol. Propranolol has no muscarinic agonist activity; it is a selective beta adrenergic antagonist. The predominance of muscarinic bronchoconstriction in this patient is an indirect consequence of removing beta-2 bronchodilatory tone.
11. A 62-year-old man with hypertension is given intravenous norepinephrine (NE) for septic shock. His blood pressure rises from 72/40 mmHg to 118/82 mmHg. However, the treating physician notes that his heart rate, which was 118 bpm before NE, falls to 88 bpm after NE administration despite NE's known ability to activate beta-1 receptors. Using adrenergic receptor and baroreceptor reflex knowledge, which of the following best explains why heart rate decreased despite beta-1 receptor activation?
A) Norepinephrine preferentially activates cardiac beta-2 receptors rather than beta-1 receptors at clinical doses, and beta-2 activation in the SA node produces bradycardia rather than tachycardia through a Gi-mediated mechanism
B) Norepinephrine's dominant cardiovascular effect is alpha-1-mediated vasoconstriction, producing a marked increase in mean arterial pressure; the resulting rise in blood pressure is detected by arterial baroreceptors (carotid sinus and aortic arch), which increase afferent vagal signaling to the nucleus tractus solitarius; this activates the parasympathetic efferent pathway to the heart via the vagus nerve, increasing SA node acetylcholine release and producing reflex bradycardia that overrides the direct beta-1 chronotropic effect of NE
C) Norepinephrine at clinical doses is a pure alpha agonist with no beta-1 activity; the heart rate fall is entirely due to alpha-1 receptor activation on SA nodal cells, which Gq-mediated IP3 production causes hyperpolarization of pacemaker cells
D) Norepinephrine activates presynaptic alpha-2 autoreceptors on cardiac sympathetic terminals, reducing NE release from the heart's own sympathetic innervation; this local NE depletion reduces intrinsic sympathetic drive to the SA node, slowing heart rate
E) Norepinephrine crosses the blood-brain barrier and activates central alpha-2 receptors in the brainstem, reducing efferent sympathetic drive to the SA node; the resulting reduction in sympathetic tone to the heart slows the pacemaker rate below the pre-NE level
ANSWER: B
Rationale:
This question illustrates the baroreceptor reflex — one of the most clinically important integrative physiological responses in cardiovascular pharmacology. Norepinephrine is a potent alpha-1 agonist, producing intense vasoconstriction and a marked rise in systemic vascular resistance (SVR) and blood pressure. Arterial baroreceptors in the carotid sinus and aortic arch detect this pressure rise and increase their afferent firing rate to the nucleus tractus solitarius (NTS) in the medulla. The NTS responds by increasing parasympathetic (vagal) outflow to the SA node and decreasing sympathetic outflow. The increased acetylcholine at the SA node activates M2 muscarinic receptors (Gi-coupled), reducing cAMP and slowing the pacemaker — producing reflex bradycardia. This reflex bradycardia is powerful enough to override and more than compensate for NE's direct beta-1 chronotropic effect, resulting in a net reduction in heart rate. This phenomenon — the baroreceptor reflex-mediated heart rate fall in response to a vasopressor — is an important clinical observation and explains why NE causes less tachycardia than epinephrine (which has more beta-2-mediated vasodilation and therefore produces less baroreceptor-driven reflex bradycardia).
Option A: Option A incorrectly states that NE preferentially activates beta-2 receptors, producing bradycardia via Gi coupling. NE has very low beta-2 affinity and beta-2 activation is associated with vasodilation and bronchodilation, not cardiac bradycardia.
Option C: Option C incorrectly states that NE is a pure alpha agonist with no beta-1 activity. NE does activate beta-1 receptors (producing positive inotropy and some direct chronotropy); the baroreceptor reflex is the reason heart rate falls despite this direct beta-1 effect.
Option D: Option D describes a real mechanism (alpha-2 autoreceptor feedback reducing local cardiac NE release) but this is not the primary explanation for the observed bradycardia in this clinical scenario. The baroreceptor reflex is the dominant and clinically recognized mechanism.
Option E: Option E incorrectly attributes the bradycardia to CNS penetration by NE activating central alpha-2 receptors. NE does not appreciably cross the blood-brain barrier; its cardiovascular effects at clinical doses are peripheral.
12. At the end of Module 1, a student reflects on the adrenergic receptor framework and asks: "Given that all three beta receptor subtypes (beta-1, beta-2, beta-3) couple to the same Gs protein and raise cAMP, why do they produce such different physiological effects?" Which of the following best answers this question and identifies the key principle that governs receptor subtype pharmacology across all of adrenergic pharmacology?
A) The three beta receptor subtypes couple to different G proteins despite sharing the Gs label — beta-1 couples to Gs in the classical sense while beta-2 couples to a Gs variant with lower adenylyl cyclase affinity and beta-3 couples to a Gs isoform that preferentially activates phosphodiesterase rather than adenylyl cyclase; the different cAMP production rates determine the different physiological effects
B) The three beta receptor subtypes do not actually all couple to Gs — current evidence shows that beta-2 receptors couple to Gi at higher agonist concentrations after receptor phosphorylation by GRK (G protein-coupled receptor kinase), switching from bronchodilation to bronchoconstriction; beta-3 receptors couple exclusively to Gi, producing effects opposite to those of beta-1
C) The different physiological effects of beta-1, beta-2, and beta-3 receptor activation despite the same Gs/cAMP second messenger are determined primarily by tissue expression — which cells express which receptor subtype determines which intracellular substrates PKA phosphorylates and therefore what physiological process is modified; beta-1 in the SA node and ventricle produces chronotropy and inotropy; beta-2 in bronchial and vascular smooth muscle produces relaxation; beta-3 in adipose and detrusor produces lipolysis and detrusor relaxation — the receptor is the address, the G protein is the signal, and the tissue is what determines the response
D) The different effects of the three beta subtypes are due entirely to differences in their affinity for cAMP-independent signaling pathways — beta-1 activates the MAP kinase pathway, beta-2 activates the PI3K/Akt pathway, and beta-3 activates the JAK/STAT pathway; cAMP elevation is a secondary, clinically irrelevant byproduct of beta receptor activation
E) The different physiological effects are due to differences in receptor desensitization rates — beta-1 receptors desensitize slowly, producing prolonged cardiac effects; beta-2 receptors desensitize rapidly, limiting bronchodilation to brief episodes; beta-3 receptors do not desensitize at all, producing permanent adipose and detrusor changes after a single agonist exposure
ANSWER: C
Rationale:
This integrative question addresses a fundamental principle in receptor pharmacology: the same second messenger (cAMP) can produce completely different physiological outcomes depending on which cell type expresses the receptor. When PKA (activated by cAMP) phosphorylates its substrates, the result depends entirely on what substrates are present in that cell: in SA nodal pacemaker cells, PKA phosphorylates HCN channels and L-type calcium channels, accelerating depolarization (chronotropy) — this is beta-1-mediated; in ventricular cardiomyocytes, PKA phosphorylates troponin I, phospholamban, and L-type channels, increasing contractility (inotropy) — also beta-1; in bronchial smooth muscle, PKA phosphorylates MLCK, inactivating it and causing relaxation (bronchodilation) — beta-2; in adipocytes, PKA phosphorylates hormone-sensitive lipase, stimulating lipolysis — beta-3; in detrusor smooth muscle, PKA phosphorylates contractile machinery to produce relaxation — beta-3. The principle is that receptor subtypes are defined by their tissue expression pattern, and the downstream consequence of cAMP elevation is determined by the biochemical substrate landscape of the target cell, not by the receptor subtype or G protein itself. This concept — that the same second messenger produces tissue-specific effects — applies throughout pharmacology.
Option A: Option A incorrectly states that the three beta subtypes couple to different Gs variants, or that beta-3 activates phosphodiesterase rather than adenylyl cyclase. All three couple to classical Gs with adenylyl cyclase activation; the differences in physiological outcome are due to tissue expression and substrate availability in the target cell, not G protein variant differences.
Option B: Option B misrepresents the clinical significance of beta-2 receptor Gi coupling: while GRK-mediated phosphorylation can promote beta-2 coupling to Gi at high agonist concentrations in experimental systems, this does not convert bronchodilation to bronchoconstriction in clinically relevant circumstances; beta-3 receptors couple to Gs (not as stated in the option), and the core assertion that standard beta agonist doses produce bronchoconstriction via Gi switching is not supported by clinical pharmacology evidence.
Option D: Option D incorrectly assigns cAMP-independent MAP kinase, PI3K/Akt, and JAK/STAT pathways as the primary mechanisms distinguishing beta receptor subtypes. While beta receptors do engage some of these pathways through beta-arrestin signaling, the primary and clinically relevant mechanism is Gs/cAMP/PKA.
Option E: Option E incorrectly attributes the different physiological effects entirely to differences in desensitization rates and incorrectly states that beta-3 receptors do not desensitize. While receptor desensitization is pharmacologically important, it does not explain why beta-1 produces cardiac inotropy while beta-2 produces bronchodilation.
BEFORE YOU MOVE ON
You have now built the receptor subtype framework that underpins all of adrenergic pharmacology. The key architecture to carry forward: alpha-1 receptors are Gq-coupled, postsynaptic, and mediate smooth muscle contraction including vasoconstriction; alpha-2 receptors are Gi-coupled, predominantly presynaptic and central, and reduce NE release and sympathetic outflow; beta-1 receptors are Gs-coupled and expressed in the heart, mediating positive chronotropy and inotropy; beta-2 receptors are Gs-coupled and expressed in smooth muscle of the bronchi and vasculature, mediating relaxation; beta-3 receptors are Gs-coupled and expressed in adipose tissue and the bladder, mediating lipolysis and detrusor relaxation. The baroreceptor reflex and the presynaptic autoreceptor feedback loop are integrative mechanisms that shape how drugs targeting these receptors actually behave in patients. Module 2 will apply this framework to the catecholamine agonists — epinephrine, norepinephrine, dopamine, and dobutamine — where you will use everything from Module 1 to predict receptor profiles, hemodynamic effects, and clinical applications.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.